AAAAAA

   
Results: 1-25 | 26-33
Results: 1-25/33

Authors: AGUNDEZ JAG GALLARDO L MARTINEZ C GERVASINI G BENITEZ J
Citation: Jag. Agundez et al., MODULATION OF CYP1A2 ENZYME-ACTIVITY BY INDOLEAMINES - INHIBITION BY SEROTONIN AND TRYPTAMINE, Pharmacogenetics, 8(3), 1998, pp. 251-258

Authors: CARRILLO JA RAMOS SI AGUNDEZ JAG MARTINEZ C BENITEZ J
Citation: Ja. Carrillo et al., ANALYSIS OF MIDAZOLAM AND METABOLITES IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - PROBE OF CYP3A, Therapeutic drug monitoring, 20(3), 1998, pp. 319-324

Authors: MARTINEZ C AGUNDEZ JAG OLIVERA M LLERENA A RAMIREZ R HERNANDEZ M BENITEZ J
Citation: C. Martinez et al., INFLUENCE OF GENETIC ADMIXTURE ON POLYMORPHISMS OF DRUG-METABOLIZING-ENZYMES - ANALYSES OF MUTATIONS ON NAT2 AND CYP2E1 GENES IN A MIXED HISPANIC POPULATION, Clinical pharmacology and therapeutics, 63(6), 1998, pp. 623-628

Authors: AGUNDEZ JAG MARTINEZ C OLIVERA M GALLARDO L LADERO JM ROSADO C PRADOS J RODRIGUEZMOLINA J RESEL L BENITEZ J
Citation: Jag. Agundez et al., EXPRESSION IN HUMAN PROSTATE OF DRUG-METABOLIZING AND CARCINOGEN-METABOLIZING ENZYMES - ASSOCIATION WITH PROSTATE-CANCER RISK, British Journal of Cancer, 78(10), 1998, pp. 1361-1367

Authors: AGUNDEZ JAG RAMIREZ R HERNANDEZ M LLERENA A BENITEZ J
Citation: Jag. Agundez et al., MOLECULAR HETEROGENEITY AT THE CYP2D GENE LOCUS IN NICARAGUANS - IMPACT OF GENE-FLOW FROM EUROPE, Pharmacogenetics, 7(4), 1997, pp. 337-340

Authors: GULLSTEN H AGUNDEZ JAG BENITEZ J LAARA E LADERO JM DIAZRUBIO M FERNANDEZSALGUERO P GONZALEZ F RAUTIO A PELKONEN O RAUNIO H
Citation: H. Gullsten et al., CYP2A6 GENE POLYMORPHISM AND RISK OF LIVER-CANCER AND CIRRHOSIS, Pharmacogenetics, 7(3), 1997, pp. 247-250

Authors: MARTINEZ C AGUNDEZ JAG GERVASINI G MARTIN R BENITEZ J
Citation: C. Martinez et al., TRYPTAMINE - A POSSIBLE ENDOGENOUS SUBSTRATE FOR CYP2D6, Pharmacogenetics, 7(2), 1997, pp. 85-93

Authors: MARTINEZ C AGUNDEZ JAG GERVASINI G MARTIN R BENITEZ J
Citation: C. Martinez et al., TRYPTAMINE - A POSSIBLE ENDOGENOUS SUBSTRATE FOR CYP2D6, Pharmacogenetics, 7(2), 1997, pp. 85-93

Authors: AGUNDEZ JAG JIMENEZJIMENEZ FJ TEJEDA R LEDESMA MC ORTIPAREJA M GASALLA T MOLINA JA RUIZ J CORIA F DUARTE J VAZQUEZ A LADERO JM BENITEZ J
Citation: Jag. Agundez et al., CYP2D6 POLYMORPHISM IS NOT ASSOCIATED WITH ESSENTIAL TREMOR, European neurology, 38(2), 1997, pp. 99-104

Authors: JAIME MTE PENCO JMM AGUNDEZ JAG LOSCOS MJC RODRIGUEZ SS MARTINEZ FB DETEJADA RG ALVAREZ EL RODRIGUEZ JB
Citation: Mte. Jaime et al., URINARY-BLADDER CANCER IN A GIRL WITH A SLOW-ACETYLATOR GENOTYPE AND TREATED WITH SULFASALAZINE, British Journal of Urology, 80(1), 1997, pp. 151-152

Authors: AGUNDEZ JAG RODRIGUEZ I OLIVERA M LADERO JM GARCIA MA RIBERA JM BENITEZ J
Citation: Jag. Agundez et al., CYP2D6, NAT2 AND CYP2E1 GENETIC POLYMORPHISMS IN NONAGENARIANS, Age and ageing, 26(2), 1997, pp. 147-151

Authors: AGUNDEZ JAG OLIVERA M LADERO JM RODRIGUEZLESCURE A LEDESMA MC DIAZRUBIO M MEYER UA BENITEZ J
Citation: Jag. Agundez et al., INCREASED RISK FOR HEPATOCELLULAR-CARCINOMA IN NAT2-SLOW ACETYLATORS AND CYP2D6-RAPID METABOLIZERS, Pharmacogenetics, 6(6), 1996, pp. 501-512

Authors: AGUNDEZ JAG OLIVERA M MARTINEZ C LADERO JM BENITEZ J
Citation: Jag. Agundez et al., IDENTIFICATION AND PREVALENCE STUDY OF 17 ALLELIC VARIANTS OF THE HUMAN NAT2 GENE IN A WHITE-POPULATION, Pharmacogenetics, 6(5), 1996, pp. 423-428

Authors: AGUNDEZ JAG MENAYA JG TEJEDA R LAGO F CHAVEZ M BENITEZ J
Citation: Jag. Agundez et al., GENETIC-ANALYSIS OF THE NAT2 AND CYP2D6 POLYMORPHISMS IN WHITE PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS, Pharmacogenetics, 6(5), 1996, pp. 465-472

Authors: LADONA MG ABILDUA RE LADERO JM ROMAN JM PLAZA MA AGUNDEZ JAG MUNOZ JJ BENITEZ J
Citation: Mg. Ladona et al., CYP2D6 GENOTYPES IN SPANISH WOMEN WITH BREAST-CANCER, Cancer letters, 99(1), 1996, pp. 23-28

Authors: AGUNDEZ JAG BENITEZ J
Citation: Jag. Agundez et J. Benitez, DETERMINATION OF AMINOPYRINE AND DIPYRONE METABOLITES IN URINE, Therapeutic drug monitoring, 18(1), 1996, pp. 104-107

Authors: LADERO JM AGUNDEZ JAG RODRIGUEZLESCURE A DIAZRUBIO M BENITEZ J
Citation: Jm. Ladero et al., RSAI POLYMORPHISM AT THE CYTOCHROME P4502E1 LOCUS AND RISK OF HEPATOCELLULAR-CARCINOMA, Gut, 39(2), 1996, pp. 330-333

Authors: BENITEZ J MARTINEZ C AGUNDEZ JAG RAMOS S
Citation: J. Benitez et al., TRYPTAMINE - A POTENTIAL ENDOGENOUS SUBSTRATE OF CYP2D6, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 20-20

Authors: BENITEZ J AGUNDEZ JAG LADERO JM RODRIGUEZLESCURE A DIAZRUBIO M
Citation: J. Benitez et al., RSAI POLYMORPHISM AT THE CYP2E1 LOCUS AND RISK OF PRIMARY LIVER-CANCER, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 21-21

Authors: MARTINEZ C AGUNDEZ JAG OLIVERA M MARTIN R LADERO JM BENITEZ J
Citation: C. Martinez et al., LUNG-CANCER AND MUTATIONS AT THE POLYMORPHIC NAT2 GENE LOCUS, Pharmacogenetics, 5(4), 1995, pp. 207-214

Authors: AGUNDEZ JAG CARRILLO JA MARTINEZ C BENITEZ J
Citation: Jag. Agundez et al., AMINOPYRINE METABOLISM IN MAN - THE ACETYLATION OF AMINOANTIPYRINE COSEGREGATES WITH ACETYLATION OF CAFFEINE, Therapeutic drug monitoring, 17(1), 1995, pp. 1-5

Authors: AGUNDEZ JAG LEDESMA MC BENITEZ J LADERO JM RODRIGUEZLESCURE A DIAZRUBIO E DIAZRUBIO M
Citation: Jag. Agundez et al., CYP2D6 GENES AND RISK OF LIVER-CANCER, Lancet, 345(8953), 1995, pp. 830-831

Authors: AGUNDEZ JAG MARTINEZ C BENITEZ J
Citation: Jag. Agundez et al., METABOLISM OF AMINOPYRINE AND DERIVATIVES IN MAN - IN-VIVO STUDY OF MONOMORPHIC AND POLYMORPHIC METABOLIC PATHWAYS, Xenobiotica, 25(4), 1995, pp. 417-427

Authors: AGUNDEZ JAG LADERO JM OLIVERA M ABILDUA R ROMAN JM BENITEZ J
Citation: Jag. Agundez et al., GENETIC-ANALYSIS OF THE ARYLAMINE N-ACETYLTRANSFERASE POLYMORPHISM INBREAST-CANCER PATIENTS, Oncology, 52(1), 1995, pp. 7-11

Authors: AGUNDEZ JAG LEDESMA MC LADERO JM BENITEZ J
Citation: Jag. Agundez et al., PREVALENCE OF CYP2D6 GENE DUPLICATION AND ITS REPERCUSSION ON THE OXIDATIVE PHENOTYPE IN A WHITE-POPULATION, Clinical pharmacology and therapeutics, 57(3), 1995, pp. 265-269
Risultati: 1-25 | 26-33